Gregory D. Berg, PhD

home / authors / gregory-d-berg-phd

Articles

March 9th 2010

An Intervention for VA Patients With Congestive Heart Failure

Laurel A. Copeland, PhD Gregory D. Berg, PhD Donna M. Johnson, MHS Richard L. Bauer, MD

An intervention of variable intensity for congestive heart failure showed some improvements but no survival effect, suggesting a tradeoff between intervention cost and intensity and survival benefit.

November 15th 2008

Cost and Utilization Avoidance With Mail Prompts: A Randomized Controlled Trial

Gregory D. Berg, PhD Steven Silverstein, MD Eileen Thomas, RN Allan M. Korn, MD

By mailing information to their members, health plans can affect rates of medical service utilization and generate cost savings.

January 1st 2004

Determinants of Hospital Length of Stay for Cervical Dysplasia and Cervical Cancer: Does Managed Care Matter?

Gregory D. Berg, PhD Sajal K. Chattopadhyay, PhD

Latest Updated Articles

FDA approval stamp | Image Credit: Surendra - stock.adobe.com

Published: November 15th 2024 | Updated: November 19th 2024

FDA Approves Revumenib for R/R Acute Leukemia With a KMT2A Translocation

What We’re Reading: Concierge Nonprofit Hospitals; Kaiser Permanente Program for Elderly Care; Health Care Not a Top Issue Among Voters

Published: April 1st 2024 | Updated: November 5th 2024

What We're Reading: Concierge Nonprofit Hospitals; Kaiser Permanente Elderly Care Program; Health Care Not Among Top Voter Issues

Clinician giving patient a diagnosis | Image Credit: Pcess609 - stock.adobe.com

Published: October 21st 2024 | Updated: October 24th 2024

Lower Diagnostic Error Rates Found Among Hospitalized Patients During Care Transitions

Hurricane | Image credit: Satoshi Kina - stock.adobe.com

Published: September 26th 2024 | Updated: October 1st 2024

Addressing Natural Disaster Takes Cooperation, Preparation to Ensure Patient Health

Opdivo packaging | Image credit: Bristol Myers Squibb

Published: May 9th 2024 | Updated: May 21st 2024

FDA Accepts Nivolumab Subcutaneous Injection Application, With Potential to Boost Access to PD-1 Inhibitors

Published: December 17th 2024 | Updated: December 22nd 2024

ICYMI: Highlights From IMS 2024

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

Do Not Sell My Information

Terms & Conditions